Endocrinology Practice Questions

Q: Gallstones are associated with which neuroendocrine tumor?

Somatostatinoma. The correct answer is **Somatostatinoma**. **1. Why Somatostatinoma is correct:** Somatostatinomas are rare neuroendocrine tumors (NETs) that secrete excessive amounts of **somatostatin** [1]. Somatostatin is a potent inhibitory hormone. In the biliary system, it inhibits the release of **Cholecystokinin (CCK)** and directly suppresses gallbladder contractility. This leads to profound **biliary stasis**, resulting in the formation of gallstones (cholelithiasis). The classic "Somatostatinoma Syndrome" triad consists of: * **Diabetes Mellitus** (due to inhibition of insulin/glucagon) * **Cholelithiasis** (due to biliary stasis) * **Steatorrhea** (due to inhibition of pancreatic enzymes and bicarbonate) **2. Why the other options are incorrect:** * **Insulinoma:** Presents with Whipple’s triad (hypoglycemia symptoms, low plasma glucose, and relief upon glucose administration). It is not associated with gallstones. * **VIPoma:** Characterized by **WDHA Syndrome** (Watery Diarrhea, Hypokalemia, and Achlorhydria). It causes massive secretory diarrhea but does not directly cause gallstones. * **Glucagonoma:** Presents with the "4Ds": **D**ermatitis (Necrolytic Migratory Erythema), **D**iabetes, **D**eep vein thrombosis, and **D**epression. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most common location:** Somatostatinomas are most frequently found in the **pancreas** (head) or the **duodenum**. * **Psammoma bodies:** Duodenal somatostatinomas are uniquely associated with the presence of psammoma bodies on histology. * **Association:** Often associated with **MEN-1** and **Neurofibromatosis type 1 (NF-1)**. * **Octreotide Link:** Long-term therapeutic use of Octreotide (a somatostatin analogue) also carries a high risk of gallstone formation for the same physiological reasons.

Q: Which of the following statements regarding insulin resistance in diabetic patients is FALSE?

It is more common with huminsulin.. Explanation: 1. Why Option A is the correct (False) statement: Insulin resistance due to antibody formation is significantly less common with human insulin (Huminsulin) compared to older animal-derived insulins (bovine or porcine) [2]. Human insulin is produced via recombinant DNA technology and is identical to endogenous human insulin, making it far less immunogenic. Animal insulins differ by one (porcine) or three (bovine) amino acids, which triggers the production of anti-insulin antibodies (IgG), leading to immune-mediated insulin resistance [2]. 2. Analysis of other options: * Option B (True): Infections trigger the release of counter-regulatory hormones like cortisol, glucagon, and catecholamines. These hormones induce a state of acute insulin resistance and hyperglycemia [3]. * Option C (True): High titers of circulating anti-insulin IgG antibodies can neutralize injected insulin, preventing it from binding to receptors [2]. This is the classic definition of "immune insulin resistance." * Option D (True): In severe cases of immune-mediated insulin resistance (where antibody titers are very high), glucocorticoids are used therapeutically to suppress the immune system and reduce antibody production, thereby restoring insulin sensitivity [3]. 3. NEET-PG High-Yield Pearls: * Definition: Clinical insulin resistance is defined as a daily requirement of >200 units of insulin in the absence of ketoacidosis or infection. * Most Immunogenic Insulin: Bovine insulin (highest amino acid variance). * Least Immunogenic Insulin: Human insulin and insulin analogues (Lispro, Aspart). * Acanthosis Nigricans: A key clinical marker of non-immune insulin resistance (Type 2 DM/Metabolic Syndrome) [1].

Q: What is the drug of choice in an 80-year-old patient presenting with hyperglycemia and ketoacidosis?

Short acting insulin. The clinical presentation of hyperglycemia combined with ketoacidosis indicates a diagnosis of **Diabetic Ketoacidosis (DKA)** [1]. DKA is a medical emergency characterized by an absolute or relative deficiency of insulin, leading to hyperglycemia, ketonemia, and metabolic acidosis [4]. **Why Short-Acting Insulin is Correct:** The cornerstone of DKA management, regardless of the patient's age, is **Regular (Short-acting) Insulin** administered via a continuous intravenous infusion [2]. Short-acting insulin is preferred because: 1. **Rapid Onset:** It works immediately to inhibit lipolysis and ketogenesis. 2. **Titratability:** Its short half-life allows for precise dose adjustments based on hourly blood glucose and anion gap monitoring. 3. **Safety:** In an 80-year-old patient who may have underlying renal or cardiac comorbidities, the ability to quickly stop the insulin effect if hypoglycemia occurs is vital [3]. **Why Other Options are Incorrect:** * **Oral Hypoglycemic Drugs (A & C):** These are contraindicated in DKA. They are insufficient to reverse ketosis and cannot be used in acute, life-threatening metabolic crises. * **Intermediate-Acting Insulin (B & C):** Drugs like NPH have a delayed onset and a prolonged peak. They do not allow for the rapid titration required to manage the dynamic shifts in electrolytes and glucose seen during DKA treatment. **NEET-PG High-Yield Pearls:** * **Standard Protocol:** Start with an IV bolus of 0.1 U/kg, followed by a continuous infusion of 0.1 U/kg/hr. * **The Goal:** The primary goal in DKA is to **close the anion gap** (stop ketosis), not just normalize blood glucose [2]. * **Potassium Warning:** Never start insulin if serum potassium is **<3.3 mEq/L**, as insulin will shift potassium intracellularly, potentially causing fatal arrhythmias [5]. * **Fluid of Choice:** Initial resuscitation should always begin with **0.9% Normal Saline** [1].

Q: Which of the following is a symptom of hypoglycemia?

Sweating. **Explanation:** Hypoglycemia (blood glucose <70 mg/dL) triggers a dual-phase clinical response: **Autonomic (Neurogenic)** and **Neuroglycopenic** [1]. 1. **Why Sweating is Correct:** When blood glucose drops, the body activates the sympathetic nervous system and the adrenal medulla to release epinephrine and norepinephrine [2]. This "adrenergic surge" stimulates sweat glands (specifically via sympathetic cholinergic fibers), leading to **diaphoresis (sweating)** [3]. Other autonomic symptoms include tremors, palpitations, and anxiety. Sweating is a hallmark sign and is often the last autonomic symptom to be suppressed in patients with "hypoglycemia unawareness" (except in those on beta-blockers) [3]. 2. **Analysis of Incorrect Options:** * **B. Bradycardia:** Hypoglycemia typically causes **tachycardia** due to the compensatory catecholamine surge [2]. Bradycardia is not a standard feature. * **C. Chest Pain:** While severe tachycardia can trigger angina in patients with underlying CAD, chest pain is not a primary or diagnostic symptom of hypoglycemia. * **D. Breathlessness:** Dyspnea is not a classic symptom. Hypoglycemia primarily affects the CNS (confusion, seizures) and the autonomic system. **High-Yield NEET-PG Pearls:** * **Whipple’s Triad:** 1. Symptoms of hypoglycemia, 2. Low plasma glucose, 3. Relief of symptoms after glucose administration. * **Beta-Blockers Warning:** Non-selective beta-blockers can mask all autonomic symptoms of hypoglycemia (tachycardia, tremors) **except sweating**. * **Neuroglycopenic symptoms** (due to CNS glucose deprivation) include confusion, fatigue, seizures, and coma; these typically occur at lower glucose levels (<54 mg/dL) than autonomic symptoms [4].

Q: The paradoxical response of Growth Hormone (GH) release to Thyrotropin-Releasing Hormone (TRH) is seen in which condition?

Acromegaly. In a healthy individual, Growth Hormone (GH) secretion is primarily regulated by GHRH (stimulatory) and Somatostatin (inhibitory). Thyrotropin-Releasing Hormone (TRH) normally has no effect on GH levels. However, in **Acromegaly**, the somatotroph cells of the pituitary adenoma undergo "dedifferentiation" or express receptors they normally wouldn't [1]. This leads to a **paradoxical rise in GH** following the administration of TRH or GnRH in approximately 50-80% of patients [1]. **Analysis of Options:** * **Acromegaly (Correct):** The neoplastic somatotrophs lose their physiological specificity, responding to TRH with a significant increase in GH [1]. This is a classic biochemical hallmark used in functional studies of the disease. * **Prolactinoma:** While often co-secreted with GH, a pure prolactinoma typically shows an increase in Prolactin, not a paradoxical GH response to TRH [1]. * **Malnutrition:** In states of starvation or Anorexia Nervosa, GH levels are often high due to GHRH stimulation and low IGF-1 (loss of negative feedback), but the specific TRH-induced paradoxical rise is characteristic of adenomatous tissue. * **Pituitary Adenoma:** This is a general term. While acromegaly is caused by a pituitary adenoma, not all pituitary adenomas (like non-functioning ones or gonadotropinomas) exhibit this specific GH response. **High-Yield Clinical Pearls for NEET-PG:** * **Oral Glucose Tolerance Test (OGTT):** The gold standard for diagnosing Acromegaly is the failure to suppress GH below 1 ng/mL after 75g of glucose [1]. * **Paradoxical Response to Glucose:** In some acromegaly patients, glucose may actually *increase* GH levels [1]. * **Best Screening Test:** Serum **IGF-1** levels (stable throughout the day, unlike GH which is pulsatile) [1]. * **Other conditions** showing paradoxical GH rise to TRH: Renal failure, Liver cirrhosis, and poorly controlled Diabetes Mellitus.

Q: Hypercalciuria is seen in which of the following conditions?

All of the above. **Explanation:** Hypercalciuria (excessive urinary calcium excretion) occurs when the filtered load of calcium exceeds the renal tubular reabsorptive capacity. This is typically driven by hypercalcemia or defects in renal handling. 1. **Hyperparathyroidism (Option A):** Primary hyperparathyroidism is the most common cause of hypercalcemia [1]. While Parathyroid Hormone (PTH) actually *increases* calcium reabsorption in the distal tubule [2], the massive increase in bone resorption and intestinal absorption leads to a high filtered load of calcium that overwhelms the kidneys, resulting in net hypercalciuria [3]. 2. **Vitamin D Intoxication (Option B):** Excessive Vitamin D leads to increased intestinal calcium absorption and bone resorption. This suppresses PTH, which in turn decreases renal calcium reabsorption, leading to significant hypercalciuria [1]. 3. **Sarcoidosis (Option C):** In granulomatous diseases like sarcoidosis, macrophages express 1-alpha-hydroxylase, which converts 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D (Calcitriol) in an unregulated manner [2]. This mimics Vitamin D intoxication, causing hypercalcemia and subsequent hypercalciuria [1]. **Clinical Pearls for NEET-PG:** * **The "PTH Paradox":** Remember that while PTH is "calcium-sparing" for the kidneys, the **total** urinary calcium is high in hyperparathyroidism due to the sheer volume of calcium being filtered. * **Differential Diagnosis:** Always check the PTH level. If calcium is high and PTH is low, consider Sarcoidosis or Malignancy [1]. * **Complication:** Hypercalciuria is a major risk factor for the formation of calcium oxalate nephrolithiasis (kidney stones) [3]. * **Contrast:** Familial Hypocalciuric Hypercalcemia (FHH) is a key differential where you see hypercalcemia but **low** urinary calcium (due to a defective Calcium-Sensing Receptor) [1].

Q: Osteoporosis is seen in which of the following conditions?

All of the above. Osteoporosis is a skeletal disorder characterized by decreased bone mineral density (BMD) and micro-architectural deterioration, leading to increased bone fragility [3]. It can be primary or secondary to various endocrine disorders. * **Thyrotoxicosis (Option A):** Excess thyroid hormone (T3/T4) stimulates osteoclast activity more than osteoblast activity. This results in a high-turnover bone loss state, shortening the normal bone remodeling cycle and leading to a net loss of bone mass. * **Cushing’s Disease (Option B):** Chronic glucocorticoid excess is a potent cause of secondary osteoporosis [1]. It acts via multiple mechanisms: inhibiting osteoblast differentiation, increasing osteoclast survival, and decreasing intestinal calcium absorption (leading to secondary hyperparathyroidism) [1]. * **Menopause (Option C):** Estrogen deficiency is the most common cause of osteoporosis [4]. Estrogen normally inhibits bone resorption; its loss leads to increased cytokine levels (like IL-1, IL-6, and TNF-alpha) that activate osteoclasts via the RANK/RANKL pathway [2, 4]. Since all three conditions independently contribute to bone loss, **Option D (All of the above)** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site of fracture:** Vertebral body (compression fractures), followed by the neck of the femur and Colles’ fracture [1]. * **Gold Standard Investigation:** Dual-energy X-ray absorptiometry (DEXA) scan. Osteoporosis is defined as a **T-score ≤ -2.5**. * **Drug of Choice:** Bisphosphonates (e.g., Alendronate, Zoledronic acid) are the first-line treatment. They work by inhibiting osteoclast-mediated bone resorption. * **Teriparatide:** A recombinant PTH analogue; it is the only anabolic agent that stimulates new bone formation.

Question 1

Gallstones are associated with which neuroendocrine tumor?

Accepted Answer

Somatostatinoma

Answer

Insulinoma

Answer

VIPoma

Answer

Glucagonoma

Question 2

Which of the following statements regarding insulin resistance in diabetic patients is FALSE?

Accepted Answer

It is more common with huminsulin.

Answer

It may occur in the presence of infections.

Answer

It may be due to antibodies to insulin.

Answer

Use of glucocorticoids may be useful in severe cases.

Question 3

A 33-year-old woman has experienced episodes of fatigue, pleural effusion, pericardial effusion, carpal tunnel syndrome, and macrocytic anemia. What is the best test for diagnosis?

Accepted Answer

Assay for thyroid hormones

Answer

Anti-beta 2 phospholipid antibodies

Answer

Anti-smith antibody

Answer

Antinuclear antibody

Question 4

What is the drug of choice in an 80-year-old patient presenting with hyperglycemia and ketoacidosis?

Accepted Answer

Short acting insulin

Answer

Oral hypoglycemic drugs

Answer

Intermediate acting insulin

Answer

Oral drug with intermediate acting insulin

Question 5

Which of the following is a symptom of hypoglycemia?

Accepted Answer

Sweating

Answer

Bradycardia

Answer

Chest pain

Answer

Breathlessness

Question 6

The paradoxical response of Growth Hormone (GH) release to Thyrotropin-Releasing Hormone (TRH) is seen in which condition?

Accepted Answer

Acromegaly

Answer

Prolactinoma

Answer

Malnutrition

Answer

Pituitary adenoma

Question 7

Hypercalciuria is seen in which of the following conditions?

Accepted Answer

All of the above

Answer

Hyperparathyroidism

Answer

Vitamin D intoxication

Answer

Sarcoidosis

Question 8

Osteoporosis is seen in which of the following conditions?

Accepted Answer

All of the above

Answer

Thyrotoxicosis

Answer

Cushing's disease

Answer

Menopause

Question 9

Which of the following is NOT a cause of the clinical features of primary hyperaldosteronism?

Accepted Answer

Chronic congestive cardiac failure

Answer

Cushing syndrome

Answer

Adrenal adenoma

Answer

Adrenal hyperplasia

Question 10

Thyrotoxicosis can be differentiated from anxiety neurosis clinically by?

Accepted Answer

Sleeping pulse rate

Answer

Tachycardia

Answer

Moist hands

Answer

Ankle's jerk

Endocrinology — MCQs

Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?